ECSP088345A - Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina - Google Patents

Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina

Info

Publication number
ECSP088345A
ECSP088345A EC2008008345A ECSP088345A ECSP088345A EC SP088345 A ECSP088345 A EC SP088345A EC 2008008345 A EC2008008345 A EC 2008008345A EC SP088345 A ECSP088345 A EC SP088345A EC SP088345 A ECSP088345 A EC SP088345A
Authority
EC
Ecuador
Prior art keywords
compounds
pirazolopirimidinas
new
cyclin dependent
inhibitors
Prior art date
Application number
EC2008008345A
Other languages
English (en)
Inventor
Timothy J Guzi
Kartik M Keertikar
Michael Dwyer
Kamil Paruch
Marc Labroli
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP088345A publication Critical patent/ECSP088345A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Powder Metallurgy (AREA)

Abstract

En sus muchas realizaciones, la presente invención provee una nueva clase de compuestos pirazolo[1,5-a]pirimidina como inhibidores de las quinasas dependientes de ciclina, métodos de preparación de dichos compuestos, composiciones farmacéuticas que comprenden uno o más de dichos compuestos, métodos de preparación de formulaciones farmacéuticas que comprenden uno o más de dichos compuestos, y métodos de tratamiento, prevención, inhibición o mejoramiento de una o más enfermedades asociadas con las CDKs usando dichos compuestos o composiciones farmacéuticas.
EC2008008345A 2005-10-06 2008-04-04 Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina ECSP088345A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/245,401 US7196078B2 (en) 2002-09-04 2005-10-06 Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors

Publications (1)

Publication Number Publication Date
ECSP088345A true ECSP088345A (es) 2008-05-30

Family

ID=37866152

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008345A ECSP088345A (es) 2005-10-06 2008-04-04 Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina

Country Status (20)

Country Link
US (2) US7196078B2 (es)
EP (1) EP1931677B1 (es)
JP (2) JP4925226B2 (es)
KR (2) KR20080063796A (es)
CN (2) CN101321756A (es)
AR (1) AR056873A1 (es)
AU (1) AU2006302443B2 (es)
BR (1) BRPI0616987B1 (es)
CA (1) CA2624829C (es)
EC (1) ECSP088345A (es)
ES (1) ES2574782T3 (es)
IL (2) IL190510A (es)
MY (1) MY162134A (es)
NO (1) NO20082091L (es)
NZ (1) NZ567187A (es)
PE (1) PE20070496A1 (es)
RU (1) RU2441005C2 (es)
TW (2) TWI362263B (es)
WO (1) WO2007044449A2 (es)
ZA (1) ZA200802996B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US8580782B2 (en) * 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US20070082900A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
WO2008043077A2 (en) * 2006-10-05 2008-04-10 Jazwares, Inc. Jigsaw puzzle display frame
WO2008063558A2 (en) * 2006-11-17 2008-05-29 Schering Corporation Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders
EP2409700A1 (en) 2007-05-08 2012-01-25 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
JP5198562B2 (ja) * 2007-06-07 2013-05-15 メルク・シャープ・アンド・ドーム・コーポレーション 置換−３−アミノピラゾールの合成
EP2271646A1 (en) * 2008-03-31 2011-01-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
EP2288260A4 (en) 2008-06-20 2013-10-23 Genentech Inc TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
US8591943B2 (en) * 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AU2015201984B2 (en) * 2009-07-09 2016-08-04 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
EP2473041B1 (en) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2491030B1 (en) 2009-10-22 2015-07-15 Fibrotech Therapeutics PTY LTD Fused ring analogues of anti-fibrotic agents
MX2012009866A (es) * 2010-02-26 2012-09-12 Mitsubishi Tanabe Pharma Corp Compuestos pirazolopirimidina y su uso como inhibidores de fosfodiesterasa 10.
US8680271B2 (en) 2010-03-26 2014-03-25 Merck Sharp & Dohme Corp. Process for synthesizing 6-bromo-3-1-(1-methyl-1H-pyrazol-4-yl)-5-(3(R)-piperidinyl)pyrazolo[1,5-a]pyrimidin-7-amine
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
US20130196986A1 (en) * 2010-09-21 2013-08-01 Marc Labroli Triazolopyrazinones as p2x7 receptor antagonists
FR2965262A1 (fr) 2010-09-24 2012-03-30 Sanofi Aventis Derives de nicotinamide, leur preparation et leur application en therapeutique
WO2012149157A2 (en) 2011-04-26 2012-11-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN103635189B (zh) * 2011-07-01 2016-05-04 诺华股份有限公司 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
EP2755482B1 (en) 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combination of mk-1775 and mk-8776 for treating cancer
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
WO2014066795A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
MX2015010700A (es) 2013-02-21 2017-01-23 Calitor Sciences Llc Compuestos heteroaromaticos como moduladores de la p13 cinasa.
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
DK3077397T3 (da) 2013-12-06 2019-12-16 Vertex Pharma 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
PL3152212T3 (pl) 2014-06-05 2020-06-15 Vertex Pharmaceuticals Inc. Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
JP6930913B2 (ja) 2014-10-14 2021-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 炎症を阻害するためのｃｄｋ９及びｂｒｄ４阻害剤の使用法
HUE061448T2 (hu) 2014-11-16 2023-07-28 Array Biopharma Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
HK1246645A1 (zh) * 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
GB201517263D0 (en) * 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
EA201891170A1 (ru) 2015-11-18 2018-11-30 Джензим Корпорейшн Биомаркер поликистозной болезни почек и варианты его применения
RU2619932C1 (ru) * 2015-11-25 2017-05-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет" (ФГБОУ ВО "ВГУ") ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДО[3,4-е]ПИРИМИДИНЫ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ
ES2987474T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2836222T3 (es) 2016-05-18 2021-06-24 Loxo Oncology Inc Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
AU2017311691B2 (en) 2016-08-18 2021-12-02 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CA3052036A1 (en) 2017-02-03 2018-08-09 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
KR102717819B1 (ko) 2017-07-28 2024-10-14 다케다 야쿠힌 고교 가부시키가이샤 Tyk2 억제제 및 이의 용도
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
AU2018366022B2 (en) * 2017-11-07 2024-05-16 The Regents Of The University Of Michigan Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
JP7619951B2 (ja) * 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
AU2019370200B2 (en) * 2018-10-30 2024-12-19 Kronos Bio, Inc. Compounds, compositions, and methods for modulating CDK9 activity
AU2020247990A1 (en) 2019-03-26 2021-11-11 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
KR102938141B1 (ko) 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드
WO2024151112A1 (ko) * 2023-01-11 2024-07-18 주식회사 티움바이오 사이클린 의존성 키나아제 9 저해제로서의 피라졸로피리미딘 유도체
WO2024242416A1 (ko) * 2023-05-22 2024-11-28 주식회사 셀러스 신규한 cdk7 억제 화합물 및 이의 용도
CN119707984A (zh) * 2023-09-28 2025-03-28 中国科学院上海药物研究所 吡唑并三嗪及吡唑并嘧啶衍生物、其制备方法、药物组合物及其用途
EP4717312A1 (en) * 2024-09-27 2026-04-01 Perha Pharmaceuticals Pyrazolo[1,5-a]pyrimidine derivatives useful as a medicament

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100191774B1 (ko) 1991-04-22 1999-06-15 오스카 아끼히꼬 피라졸로[1,5-알파] 피리미딘 유도체 및 이것을 함유하는 항염증제
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
US5707997A (en) 1994-06-21 1998-01-13 Otsuka Pharmaceutical Factory, Inc. Pyrazolo 1,5-a!pyrimidine derivative
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
ATE355841T1 (de) 1997-12-13 2007-03-15 Bristol Myers Squibb Co Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
EP1218381B1 (en) 1999-09-30 2006-12-06 Neurogen Corporation AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES
ATE335737T1 (de) 2000-09-15 2006-09-15 Vertex Pharma Isoxazole und ihre verwendung als erk-inhibitoren
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
EP1345941A1 (fr) 2000-12-20 2003-09-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
EP1505068A4 (en) 2002-04-23 2008-03-19 Shionogi & Co PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND INHIBITOR OF NAD (P) H OXIDASE CONTAINING SAID DERIVATIVE
JP2005529919A (ja) 2002-05-10 2005-10-06 スミスクライン ビーチャム コーポレーション 治療用化合物
DE10223917A1 (de) 2002-05-29 2003-12-11 Bayer Cropscience Ag Pyrazolopyrimidine
NZ539163A (en) * 2002-09-04 2007-03-30 Schering Corp Pyrazolo[1,5-a]pyrimidine compounds useful as cyclin dependent kinase (CDK) inhibitors
KR20050057139A (ko) * 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
WO2004022561A1 (en) * 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0305559D0 (en) 2003-03-11 2003-04-16 Teijin Ltd Compounds
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
EP1667684A1 (en) 2003-09-17 2006-06-14 ICOS Corporation Use of chk1 inhibitors to control cell proliferation
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US7288124B2 (en) 2004-09-08 2007-10-30 L'oreal S.A. Heteroaromatic binuclear black direct dyes
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
DE602005014891D1 (de) 2004-12-21 2009-07-23 Schering Corp PYRAZOLOÄ1,5-AÜPYRIMIDINE ALS ANTAGONISTEN DES ADENOSIN-A2a-REZEPTORS

Also Published As

Publication number Publication date
JP2009511487A (ja) 2009-03-19
CN101321756A (zh) 2008-12-10
RU2441005C2 (ru) 2012-01-27
CA2624829C (en) 2014-05-27
JP2012072189A (ja) 2012-04-12
EP1931677A2 (en) 2008-06-18
TW201038271A (en) 2010-11-01
CN102627645A (zh) 2012-08-08
BRPI0616987A2 (pt) 2009-08-04
US7196078B2 (en) 2007-03-27
AR056873A1 (es) 2007-10-31
KR101661405B1 (ko) 2016-09-29
EP1931677B1 (en) 2016-04-20
WO2007044449A2 (en) 2007-04-19
NO20082091L (no) 2008-07-04
CA2624829A1 (en) 2007-04-19
ZA200802996B (en) 2009-03-25
PE20070496A1 (es) 2007-07-13
BRPI0616987B1 (pt) 2021-08-31
US20060128725A1 (en) 2006-06-15
AU2006302443A1 (en) 2007-04-19
NZ567187A (en) 2011-09-30
AU2006302443B2 (en) 2012-07-26
IL190510A0 (en) 2008-11-03
TW200800224A (en) 2008-01-01
TWI362263B (en) 2012-04-21
IL190510A (en) 2014-02-27
IL215929A0 (en) 2011-12-29
KR20140097558A (ko) 2014-08-06
MY162134A (en) 2017-05-31
ES2574782T3 (es) 2016-06-22
JP4925226B2 (ja) 2012-04-25
US8586576B2 (en) 2013-11-19
KR20080063796A (ko) 2008-07-07
US20070225270A1 (en) 2007-09-27
TWI372625B (en) 2012-09-21
RU2008117295A (ru) 2009-11-20
WO2007044449A3 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
ECSP088345A (es) Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
ECSP11005642A (es) Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas
BR0314001A (pt) Pirazolopirimidinas como inibidores de cinase dependente de ciclina
DOP2022000096A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
MX2009011355A (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
ATE470668T1 (de) Pyrazolopyrimidine als inhibitoren von cyclinabhängiger kinase zur behandlung von krebs
MX2009003733A (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
MY149044A (en) Pyrazolopyrimidines - derivatives as cyclin dependent kinase inhibitors
MX2009003734A (es) Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina.
ATE420883T1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
MX2009013729A (es) Imidazopirazinas como inhibidores de proteina quinasa.
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
PH12014500053A1 (en) Proteasome inhibitors
WO2004078682A3 (en) Cyclic compounds and compositions as protein kinase inhibitors
WO2008045267A3 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2007044401A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
ECSP088441A (es) Derivados de pirazolo [4,3-d]pirimidin-5-il usados como inhibidores de pde5
UY28460A1 (es) Compuestos de aminotriazol útiles como inhibidores de quinasas de proteinas